Sound Pharmaceuticals and DoD collaborate on new hearing loss guidance

By Home Page, Uncategorized

Seattle, WA

Sound Pharmaceuticals, a pioneer in the development of novel drug treatments for inner ear disease, announced today that Jonathan Kil, MD, Co-Founder and Chief Medical Officer, is a co-author on two publications from the Department of Defense’s Hearing Center of Excellence (HCE). The HCE is focused on the prevention, diagnosis, mitigation, treatment, and rehabilitation of hearing loss. HCE is congressionally directed to partner with the Department of Veterans Affairs (VA), and other organizations that support the study of auditory injury. The papers are part of a series of new guidance documents from the HCE published in the September issue of Otology & Neurotology, a leading otolaryngology journal. Read More

Sound Pharmaceuticals and Oxford collaborate on a new treatment for bipolar disorder

By Home Page
Seattle, WA and Oxford, England

 
Sound Pharmaceuticals (SPI) will collaborate with the University of Oxford on a Phase 2 clinical trial to test SPI-1005 for the treatment of bipolar disorder. Bipolar disorder is a psychiatric illness that involves both periods of mania and depression, and affects approximately one percent of adults worldwide. Unfortunately, patients have relatively few treatment options, often involving drugs such as lithium, which has significant side effects. Read More

David Guyer visionary biotech leader joins Sound Pharmaceuticals

By Home Page
Sound Pharmaceuticals is pleased to announce that David Guyer, MD has joined the company as a strategic advisor. Dr. Guyer is an accomplished academic ophthalmologist and an industry leader in the area of vision loss research and retinal drug development. Dr. Guyer is currently the Co-Founder, Chief Executive Officer and Chairman of Ophthotech which he began in 2007. As CEO, Dr. Guyer raised more than $350 million in financing including a $192 million IPO in 2013 and has advanced the lead program into Phase 3 clinical trials.

Read More